CancerNCT03878940
A Feasibility Study of Direct Access to an Abdominal ´Yes-No´ Pathway for Primary Care Patients
A study testing Abdominal ´yes-no´ pathway in people with Cancer and Primary Health Care, run by University of Aarhus at 1 site in Denmark.
Trial summary
Background To optimise cancer outcome in Denmark, cancer diagnostic pathways should, beside cancer patient pathways (CPP) for alarm symptoms, also include a pathway for patients with vague and non-specific symptoms. Read more about this study
- Who is it for?
- Ages 30 years and older
- Conditions the study is for
- Cancer, Primary Health Care
- What is being tested?
- Abdominal ´yes-no´ pathway
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Apr 2019to 31 Mar 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- GPs in the municipality of Silkeborg can refer patients with the following criteria to Silkeborg Regional Hospital:
- Men and women ≥30 years old presenting with vague and non-specific abdominal symptoms for at least 3-4 weeks
Who cannot join
- Men or women who fulfil access criteria for the CPPs.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Feasibility Study of Direct Access to a Newly Developed Abdominal ´Yes-No´ Pathway for Primary Care Patients With Vague and Non-specific Abdominal Symptoms
Background To optimise cancer outcome in Denmark, cancer diagnostic pathways should, beside cancer patient pathways (CPP) for alarm symptoms, also include a pathway for patients with vague and non-specific symptoms. Research has demonstrated that 50% of all cancers do not qualify for specific CPPs, although the majority of patients initially present symptoms in general practice.
Hypothesis Direct access to an abdominal 'yes-no' pathway is feasible in general practice. Aim The aim of this study is to assess the implementation and clinical implications of direct access to an abdominal 'yes-no' pathway for primary care patients with vague and non-specific abdominal symptoms Materials and methods The study is a feasibility study in which all general practitioners (GPs) in the municipality of Silkeborg in Central Denmark Region are offered direct access to a newly developed abdominal ´yes-no´ pathway for both men and women aged 30 years or above, who present vague and non-specific abdominal symptoms in primary care. The abdominal ´yes-no´ pathway consists of: 1) Medical and objective examination, 2) Selected blood samples and a Fecal Immunochemical test (FIT), and 3) Abdominal ultrasound (US) and transvaginal US (TVUS) (for women).
Perspectives This study will provide important knowledge on how to improve abdominal cancer diagnostics in general practice.
Read the detailed description
Background Danish cancer patients have poorer cancer outcome compared to other European cancer patients. Earlier cancer diagnosis is a pivotal step to improve the prognosis, and there seems to be opportunity for improvement, as e.g. colon cancer is more often diagnosed at an advanced stage in Denmark than in other countries.
In Denmark, more than 11,500 abdominal cancers are registered yearly, which corresponds to 31% of all newly diagnosed cancers. The majority (75-85%) of cancer patients initially present symptoms to their GP. But only half of the patients present an alarm symptom, while 20% present serious non-specific symptoms, and 30% present vague non-specific symptoms. Site-specific CPPs for alarm symptoms were implemented in Denmark in 2008/2009 to optimise the diagnostic route for cancer. In 2012, a new Danish CPP was implemented to target patients with serious non-specific symptoms and signs of cancer (NSSC-CPP). No pathway exists for patients with vague abdominal symptoms.
Presenting in general practice with abdominal symptoms is very common. Most abdominal symptoms presented in general practice can be signs of serious disease in the abdomen and the pelvic region. However, in most cases, the symptoms are benign, self-limiting and harmless. Still, more than ten different cancer types can cause these symptoms, but clinically it is often difficult to distinguish between the symptoms.
For patients presenting vague symptoms to the GP, the ideal strategy could be easy and direct access to relevant investigations rather than a wait-and-see approach or referral to a CPP.
Aim The study sets out to investigate the need for an abdominal 'yes-no' pathway for primary care patients with vague and non-specific abdominal symptoms, how it could be clinically organised and integrated, and whether such pathway is feasible.
Material and methods Prior to the current intervention, a developmental part was conducted in 2018. It consisted of focus group meetings with 16 selected specialist, with expertise regarding patients with abdominal symptoms in general practice and abdominal cancers and other abdominal diseases.
The investigators assembled two focus groups during autumn 2017, each comprising the following experts: two GPs, a physician with expertise in gastroenterology, an abdominal surgeon, a radiologist, a gynecologist, a microbiologist and a physician in clinical biochemistry. The focus groups aimed to develop and agree on an abdominal 'yes-no' pathway using the following criteria: 1) reduce the time to diagnosis, 2) avoid unnecessary tests, 3) increase patient safety and minimise missed opportunities, 4) order the specific investigations temporally, 5) place responsibility and develop a structure and 6) illustrate an optimal pathway.
From January to September 2018, the investigators completed two meetings in each focus group, after which the investigators compared the results and gathered the groups in a common session. From the literature and the preliminary results of an yet unpublished register study, the investigators were able to present the clinical challenges to the participants during the meetings. Moreover, the possible access to investigations was presented (laboratory tests, imaging, endoscopies and access to specialist advice). Based on discussions during the meetings, the investigators developed an abdominal ´yes-no´ pathway. The abdominal ´yes-no´ pathway consists of three steps; 1) Medical and objective examination, 2) Selected blood samples and a FIT, and 3) Abdominal US and TVUS. The GP continues to hold responsibility for follow-up, while hospital examinations are performed on an outpatient basis with direct access from general practice. After finished investigation, the results from the tests will all return electronically to the referring GP.
The intervention is planned to initiate as a feasibility study at Silkeborg Regional Hospital from 1 April 2019. Agreements have been made with the hospital management, and an information meeting has taken place in March 2019 at the hospital. All GPs in the municipality of Silkeborg were invited to participate. An illustration, to hand out for involved GPs has been developed. Prior to investigation, all patients referred to the abdominal ´yes-no´ pathway will receive a consent form with information of the study. The inclusion period is 6 months from 1 April 2019 to 30 September 2019, after which the investigators will monitor the patients for up to 6 months.
The study has been approved and is registered in the Record of Processing Activities at the Research Unit of General Practice in Aarhus in accordance with the provisions of the General Data Protection Regulation (GDPR). The Central Denmark Region Committees on Health Research Ethics has concluded that the study can be conducted without an approval from the Committees (Request 16/2019). Further, The committee on multi-practice studies under the Danish College of General Practitioners (DSAM) and the Organisation of General Practitioners in Denmark (PLO) have been asked to recommend GPs to participate in the study.
The analyses will be descriptive with frequencies and incidence rates of use of the pathway corrected for practice population. An overview of all findings in the abdominal 'yes-no' pathway will be provided, and possible side effects will be assessed.
Perspectives The study will provide new important knowledge of patients with vague and non-specific abdominal symptoms, who do not fulfil access criteria for the CPPs, but for whom the diagnosis of an abdominal cancer should not be missed. This may improve the diagnostics of abdominal cancers or other serious abdominal disease in the future, aiming to reduce time to diagnosis.
- Conditions
- Cancer, Primary Health Care
- Being tested
- Abdominal ´yes-no´ pathway
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Abdominal ´yes-no´ pathwayDiagnostic test
A set of blood samples, a FIT, and an abdominal US (and a TVUS in women)
| Study group | Role | What they receive |
|---|---|---|
| Primary care patients | Other | All GPs in the municipality of Silkeborg will be invited to participate. Any patient can be referred to the abdominal ´yes-no´ pathway, independently of their willingness to give one´s consent. Receives: Diagnostic Test: Abdominal ´yes-no´ pathway |
What is being measured
The primary outcome is the main question the study is designed to answer.
The proportion of general practices using the abdominal 'yes-no' pathway
In the municipality of Silkeborg, 23 general practices will be offered direct access to the abdominal 'yes-no' pathway.
Measured: 6 months
Number of patients referred to the abdominal 'yes-no' pathway
The number of patients referred to the abdominal 'yes-no' pathway, both overall from all 23 general practices in the municipality of Silkeborg, and per general practice. We expect one eligible patient from each GP every third week.
Measured: 6 months
Indications used for requesting the abdominal 'yes-no' pathway
Measured: 6 months
Health care use within 6 months of intervention
'Health care use´ is defined as consultations, imaging and endoscopies performed in both primary and secondary care. Data will be collected through the Danish National Patient Registry and the Danish National Health Service Register.
Measured: 6 months
Secondary outcomes (2)
Number of patients with a diagnosis of cancer or another serious disease in the abdomen
Data from The Danish Pathology Register will be used to investigate for cancer diagnoses and other serious diseases up to 6 months after the diagnostics performed through the abdominal ´yes-no´ pathway.
Measured: 6 months
Number of patients with unintended side effects
Number of patients with unintended side effect in consequence of the diagnostics performed in and caused by the abdominal 'yes-no' pathway.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2019
- Study start1 Apr 2019
- Primary completion30 Sep 2019
- Study completion31 Mar 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by University of AarhusThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 27 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Aarhus
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Peter Vedsted, Study director, Research Unit of General Practice, Aarhus, DenmarkHenry Jensen, Study chair, Research Unit of General Practice, Aarhus, DenmarkHenning Gronbaek, Study chair, Dept. of Hepatology and Gastroenterology, Aarhus University Hospital, DenmarkHenning Glerup, Study chair, Diagnostic Center, Silkeborg Regional Hospital, DenmarkNanna Holt Jessen, Principal investigator, Research Unit of General Practice, Aarhus, Denmark
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03878940
- Sponsor's protocol ID
- 16/2019
- Status last verified
- Apr 2020
- First submitted
- 27 Feb 2019
- Last updated
- 16 Apr 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Feasibility Study of Direct Access to a Newly Developed Abdominal ´Yes-No´ Pathway for Primary Care Patients With Vague and Non-specific Abdominal Symptoms
- ClinicalTrials.gov ID
- NCT03878940
- Acronym / sponsor ID
- 16/2019
- Conditions
- Cancer, Primary Health Care
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 27 participants (actual)
- Lead sponsor
- University of AarhusUniversity, hospital or other
- Study start
- 1 Apr 2019 (actual)
- Primary completion
- 30 Sep 2019 (actual)
- Study completion
- 31 Mar 2020 (actual)
- First posted
- 18 Mar 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background To optimise cancer outcome in Denmark, cancer diagnostic pathways should, beside cancer patient pathways (CPP) for alarm symptoms, also include a pathway for patients with vague and non-specific symptoms. Research has demonstrated that 50% of all cancers do not qualify for specific CPPs, although the majority of patients initially present symptoms in general practice.
Hypothesis Direct access to an abdominal 'yes-no' pathway is feasible in general practice. Aim The aim of this study is to assess the implementation and clinical implications of direct access to an abdominal 'yes-no' pathway for primary care patients with vague and non-specific abdominal symptoms Materials and methods The study is a feasibility study in which all general practitioners (GPs) in the municipality of Silkeborg in Central Denmark Region are offered direct access to a newly developed abdominal ´yes-no´ pathway for both men and women aged 30 years or above, who present vague and non-specific abdominal symptoms in primary care. The abdominal ´yes-no´ pathway consists of: 1) Medical and objective examination, 2) Selected blood samples and a Fecal Immunochemical test (FIT), and 3) Abdominal ultrasound (US) and transvaginal US (TVUS) (for women).
Perspectives This study will provide important knowledge on how to improve abdominal cancer diagnostics in general practice.
Detailed description
Background Danish cancer patients have poorer cancer outcome compared to other European cancer patients. Earlier cancer diagnosis is a pivotal step to improve the prognosis, and there seems to be opportunity for improvement, as e.g. colon cancer is more often diagnosed at an advanced stage in Denmark than in other countries.
In Denmark, more than 11,500 abdominal cancers are registered yearly, which corresponds to 31% of all newly diagnosed cancers. The majority (75-85%) of cancer patients initially present symptoms to their GP. But only half of the patients present an alarm symptom, while 20% present serious non-specific symptoms, and 30% present vague non-specific symptoms. Site-specific CPPs for alarm symptoms were implemented in Denmark in 2008/2009 to optimise the diagnostic route for cancer. In 2012, a new Danish CPP was implemented to target patients with serious non-specific symptoms and signs of cancer (NSSC-CPP). No pathway exists for patients with vague abdominal symptoms.
Presenting in general practice with abdominal symptoms is very common. Most abdominal symptoms presented in general practice can be signs of serious disease in the abdomen and the pelvic region. However, in most cases, the symptoms are benign, self-limiting and harmless. Still, more than ten different cancer types can cause these symptoms, but clinically it is often difficult to distinguish between the symptoms.
For patients presenting vague symptoms to the GP, the ideal strategy could be easy and direct access to relevant investigations rather than a wait-and-see approach or referral to a CPP.
Aim The study sets out to investigate the need for an abdominal 'yes-no' pathway for primary care patients with vague and non-specific abdominal symptoms, how it could be clinically organised and integrated, and whether such pathway is feasible.
Material and methods Prior to the current intervention, a developmental part was conducted in 2018. It consisted of focus group meetings with 16 selected specialist, with expertise regarding patients with abdominal symptoms in general practice and abdominal cancers and other abdominal diseases.
The investigators assembled two focus groups during autumn 2017, each comprising the following experts: two GPs, a physician with expertise in gastroenterology, an abdominal surgeon, a radiologist, a gynecologist, a microbiologist and a physician in clinical biochemistry. The focus groups aimed to develop and agree on an abdominal 'yes-no' pathway using the following criteria: 1) reduce the time to diagnosis, 2) avoid unnecessary tests, 3) increase patient safety and minimise missed opportunities, 4) order the specific investigations temporally, 5) place responsibility and develop a structure and 6) illustrate an optimal pathway.
From January to September 2018, the investigators completed two meetings in each focus group, after which the investigators compared the results and gathered the groups in a common session. From the literature and the preliminary results of an yet unpublished register study, the investigators were able to present the clinical challenges to the participants during the meetings. Moreover, the possible access to investigations was presented (laboratory tests, imaging, endoscopies and access to specialist advice). Based on discussions during the meetings, the investigators developed an abdominal ´yes-no´ pathway. The abdominal ´yes-no´ pathway consists of three steps; 1) Medical and objective examination, 2) Selected blood samples and a FIT, and 3) Abdominal US and TVUS. The GP continues to hold responsibility for follow-up, while hospital examinations are performed on an outpatient basis with direct access from general practice. After finished investigation, the results from the tests will all return electronically to the referring GP.
The intervention is planned to initiate as a feasibility study at Silkeborg Regional Hospital from 1 April 2019. Agreements have been made with the hospital management, and an information meeting has taken place in March 2019 at the hospital. All GPs in the municipality of Silkeborg were invited to participate. An illustration, to hand out for involved GPs has been developed. Prior to investigation, all patients referred to the abdominal ´yes-no´ pathway will receive a consent form with information of the study. The inclusion period is 6 months from 1 April 2019 to 30 September 2019, after which the investigators will monitor the patients for up to 6 months.
The study has been approved and is registered in the Record of Processing Activities at the Research Unit of General Practice in Aarhus in accordance with the provisions of the General Data Protection Regulation (GDPR). The Central Denmark Region Committees on Health Research Ethics has concluded that the study can be conducted without an approval from the Committees (Request 16/2019). Further, The committee on multi-practice studies under the Danish College of General Practitioners (DSAM) and the Organisation of General Practitioners in Denmark (PLO) have been asked to recommend GPs to participate in the study.
The analyses will be descriptive with frequencies and incidence rates of use of the pathway corrected for practice population. An overview of all findings in the abdominal 'yes-no' pathway will be provided, and possible side effects will be assessed.
Perspectives The study will provide new important knowledge of patients with vague and non-specific abdominal symptoms, who do not fulfil access criteria for the CPPs, but for whom the diagnosis of an abdominal cancer should not be missed. This may improve the diagnostics of abdominal cancers or other serious abdominal disease in the future, aiming to reduce time to diagnosis.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Primary care patients | Other | Diagnostic Test: Abdominal ´yes-no´ pathwayAll GPs in the municipality of Silkeborg will be invited to participate. Any patient can be referred to the abdominal ´yes-no´ pathway, independently of their willingness to give one´s consent. |
Who may qualify
- Ages
- 30 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- GPs in the municipality of Silkeborg can refer patients with the following criteria to Silkeborg Regional Hospital:
- Men and women ≥30 years old presenting with vague and non-specific abdominal symptoms for at least 3-4 weeks
Key exclusion criteria (1 listed)
- Men or women who fulfil access criteria for the CPPs.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Abdominal ´yes-no´ pathwayA set of blood samples, a FIT, and an abdominal US (and a TVUS in women) | Diagnostic test | Primary care patients |
Primary outcome
The proportion of general practices using the abdominal 'yes-no' pathway
Time frame: 6 months
In the municipality of Silkeborg, 23 general practices will be offered direct access to the abdominal 'yes-no' pathway.
Number of patients referred to the abdominal 'yes-no' pathway
Time frame: 6 months
The number of patients referred to the abdominal 'yes-no' pathway, both overall from all 23 general practices in the municipality of Silkeborg, and per general practice. We expect one eligible patient from each GP every third week.
Indications used for requesting the abdominal 'yes-no' pathway
Time frame: 6 months
Health care use within 6 months of intervention
Time frame: 6 months
'Health care use´ is defined as consultations, imaging and endoscopies performed in both primary and secondary care. Data will be collected through the Danish National Patient Registry and the Danish National Health Service Register.
2 secondary outcomes
Number of patients with a diagnosis of cancer or another serious disease in the abdomen
Time frame: 6 months
Number of patients with unintended side effects
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2020.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Peter Vedsted study director
Research Unit of General Practice, Aarhus, Denmark
Henry Jensen study chair
Research Unit of General Practice, Aarhus, Denmark
Henning Gronbaek study chair
Dept. of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Abdominal ´yes-no´ pathway in people with Cancer and Primary Health Care, run by University of Aarhus at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The proportion of general practices using the abdominal 'yes-no' pathway (time frame: 6 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2020.